Combination of Cinobufacini and Doxorubicin Increases Apoptosis of Hepatocellular Carcinoma Cells through the Fas- and Mitochondria-Mediated Pathways.
Am J Chin Med
; 45(7): 1537-1556, 2017.
Article
em En
| MEDLINE
| ID: mdl-28946772
ABSTRACT
Cinobufacini, a traditional Chinese medicine, has been used widely for cancer treatment, such as hepatocellular carcinoma (HCC), sarcoma, and leukemia. Previous studies done by our lab indicated that cinobufacini could suppress HCC cells through mitochondria-mediated and Fas-mediated apoptotic pathways. Here, we use a combination of cinobufacini and doxorubicin to inhibit the growth of HCC cells. The combination group induced more significant apoptosis by affecting proteins and RNA of apoptosis-related elements, such as Bcl-2, Bax, Bid, and cytochrome c. Furthermore, cinobufacini, as a mixture of a number of components, had stronger apoptosis-inducing activity than particular individual components or a simple mixture of a few components. Overall, these results suggested that the combination of cinobufacini and doxorubicin may provide a new strategy for inhibiting the proliferation of HCC cells.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Medicamentos de Ervas Chinesas
/
Transdução de Sinais
/
Doxorrubicina
/
Sobrevivência Celular
/
Apoptose
/
Carcinoma Hepatocelular
/
Receptor fas
/
Proliferação de Células
/
Venenos de Anfíbios
/
Neoplasias Hepáticas
Limite:
Humans
Idioma:
En
Revista:
Am J Chin Med
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Japão